TGAT
93M1k
, Last price
EUR
Name
MPH Health Care AG
Chart & performance
P/E
—
P/S
—
EPS
6.84
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
-0.64%
Div Yld LY
—
Div Yld TTM
—
Revenues
364m
+5,860.79%
Net income
29m
-8.56%
CFO
7m
+291.82%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MPH Health Care AG is a German-based investment firm with a primary focus on the healthcare sector. The company's portfolio includes the production and distribution of medicinal products designed to treat serious illnesses like cancer, HIV, and various other chronic conditions. Beyond pharmaceuticals, it also delivers medical aesthetic treatments, develops and markets a diverse array of pharmaceutical and medical items, and furnishes related services and specialized medical devices for use in aesthetic surgery and cosmetic dermatology. Furthermore, its operations extend to supplying cytostatic solutions and involvement in real estate ventures. Established in Berlin in 2008, the company adopted its current name, MPH Health Care AG, in 2017, having previously been known as MPH Mittelständische Pharma Holding AG. It functions as a subsidiary of Magnum AG.
Key people
Andrea Grosse
Chairwoman of the Supervisory Board · since 2010
Patrick Brenske
Sole Member of the Management Board · since 2017
Deputy Chairman of the Supervisory Board
Sabine Meck
Member of the Supervisory Board · since 2017
Headquarters & legal address
Grünauer Straße 5
Berlin, BE 12557
DE
Berlin, BE 12557
DE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||